Travaux scientifiques

Doç. Dr. Mutlu Hızal

101 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Source : OpenAlex

  2. Long-Term Outcomes of Patients Undergoing Conversion Surgery After Induction Chemotherapy: Turkish Oncology Group Study

    Medicina, 2025

    DOI 10.3390/medicina61050776 PMID 40428735 Texte intégral en libre accèsSource : OpenAlex

  3. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-15287-2 PMID 41275151 Texte intégral en libre accèsSource : OpenAlex

  4. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  5. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  6. Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70169 PMID 41045097 3 citations (OpenAlex) Source : OpenAlex

  7. The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer

    Expert Review of Anticancer Therapy, 2025

    DOI 10.1080/14737140.2025.2490289 PMID 40200428 3 citations (OpenAlex) Source : OpenAlex

  8. Large Unstained Cells: A Predictive Biomarker for Recurrence and Survival in Resected Gastric Cancer

    Medicina, 2025

    DOI 10.3390/medicina61020208 PMID 40005326 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  9. Prognostic Significance of ARID1A, PTEN and PD-L1 Expressions and MMR Status in Colorectal Cancer Tissue

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2024.103340 Texte intégral en libre accèsSource : OpenAlex

  10. Immunotherapy for Small Cell Lung Cancer

    Springer eBooks, 2025

    DOI 10.1007/978-3-032-00769-8_244 Source : OpenAlex

  11. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

    BMC Cancer, 2024

    DOI 10.1186/s12885-024-13357-5 PMID 39736618 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  12. Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesis

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-72736-x PMID 39266694 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  13. Are the clinical trials in lung cancer an advantage for patients in developing countries?

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e20523 1 citation (OpenAlex) Source : OpenAlex

  14. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

    Future Oncology, 2023

    DOI 10.2217/fon-2022-1287 PMID 37133230 22 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  15. 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study

    ESMO Open, 2023

    DOI 10.1016/j.esmoop.2023.101440 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  16. Tamoxifen related chorioretinal structural changes

    Cutaneous and Ocular Toxicology, 2023

    DOI 10.1080/15569527.2023.2220388 PMID 37272809 1 citation (Europe PMC) Source : ORCID

  17. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.41196 Texte intégral en libre accèsSource : OpenAlex

  18. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.

    Journal of cancer research and therapeutics, 2023

    DOI 10.4103/jcrt.jcrt_353_22 PMID 37006071 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  19. Investigation of The Effect of Adjuvant Endocrine Treatment on Depression, Sleep Quality and Sexual Function in Hormone Receptor-Positive Early-Stage Breast Cancer

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.24654 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  20. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

    Journal of Oncological Sciences, 2023

    DOI 10.37047/jos.2023-96148 Texte intégral en libre accèsSource : OpenAlex

  21. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_1104_21 PMID 36510987 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  22. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04252-2 PMID 36048274 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  23. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  24. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04087-x PMID 35689097 11 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  25. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2022

    DOI 10.1016/j.clgc.2022.07.006 PMID 35970759 6 citations (Europe PMC) Source : OpenAlex

  26. The relationship between adjuvant chemotherapy and thiol-disulfide compounds

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_32_20 PMID 36149169 7 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  27. The Real-Life Efficacy of the Second Line Treatment Strategy in Advanced Pancreas Cancer

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-88853 Texte intégral en libre accèsSource : OpenAlex

  28. Immunotherapy for Small Cell Lung Cancer

    Springer eBooks, 2022

    DOI 10.1007/978-3-030-80962-1_244-1 Source : OpenAlex

  29. 1405P Efficacy and safety of perioperative FLOT (5-FU, LV, oxaliplatin, docetaxel) chemotherapy in gastric and gastroesophageal junction adenocarcinoma: Real-life data from Turkish oncology group

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.1514 Texte intégral en libre accèsSource : OpenAlex

  30. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

    Journal of Cancer Research and Clinical Oncology, 2021

    DOI 10.1007/s00432-021-03748-7 PMID 34331582 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  31. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2021

    DOI 10.1007/s00432-020-03501-6 PMID 33433657 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  32. Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0717 PMID 34726480 7 citations (Europe PMC) Source : OpenAlex

  33. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.6_suppl.321 1 citation (OpenAlex) Source : OpenAlex

  34. Birinci basamak alektinib tedavisi alan ALK mutasyonu pozitif akciğer kanseri hastalarının klinik özelliklerinin değerlendirilmesi

    Tuberkuloz ve Toraks, 2021

    DOI 10.5578/tt.20219704 PMID 34581153 Texte intégral en libre accèsSource : OpenAlex

  35. The Real-Life Efficacy And Safety of Osimertinib In Pretreated Advanced Non-Small Cell Lung Cancer Patients With T790M Mutation: A Turkish Oncology Group Study

    2021

    DOI 10.21203/rs.3.rs-486874/v1 Texte intégral en libre accèsSource : ORCID

  36. The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement

    Journal of Cancer Research and Clinical Oncology, 2021

    DOI 10.1007/s00432-021-03546-1 PMID 33528638 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  37. Hepatoselüler Kanserde Etiyopatogenez, Önleme, Evreleme

    2021

    Source : OpenAlex

  38. Hepato-Pankreato Biliyer Sistem Kanserleri

    AYBU AVESIS, 2021

    Source : OpenAlex

  39. PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)

    AYBU AVESIS, 2020

    Source : OpenAlex

  40. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219900908 PMID 32054412 9 citations (Europe PMC) Source : OpenAlex

  41. PROGNOSTIC AND PREDICTIVE MARKERSOF FOLFIRI/AFLIBERCEPT IN PATIENTS WITHMETASTATIC COLORECTAL CANCER (TOG STUDY)Cihan Erol1, Mutlu Hızal2, Irem Bilgetekin3, Sinem Akbas4,Duygu Bayir Garbioglu5, Jamshid Hamdard6, Cagatay Arslan7,Alper Sevinc8, Ahmet Kucukarda9, Dilek Gurgenyatagi10, EmreCakir11, Aykut Demirkiran12, Murat Araz12, Sercan On13, IzzetDogan14, Atike Pinar Erdogan15, Sinan Koca16, Pinar Kubilay17,Onder Eren18, Deniz Tataroglu Ozyukseler19, Mahmut EmreYildirim19, Ebru Cilbir20, Emir Celik21, Aykut Bahceci22, HalilTaskaynatan23, Abdulkerim Oyman24, Gulhan Ipek Deniz25,Serkan Menenekse26, Engin Kut26, Ahmet Gulmez27, AbdullahSakin28, Erdinc Nayir29, Ramazan Acar30, Seda Kahraman1,Erdem Sen31, Ali Inal32, Serdar Turhal33, Ali Osman Kaya34, SemraPaydas35, Didem Tastekin14, Ilhan Hacıbekiroglu11, Irfan Cicin9,Ahmet Bilici6, Didem Sener Dede1, Muhammed Bulent Akinci1,Nil Molinas Mandel36, Berna Oksuzoglu3, Dogan Uncu2, BulentYalcin1, Mehmet Artac12, Mehmet Ali Nahit Sendur1

    AYBU AVESIS, 2020

    Source : OpenAlex

  42. Evaluation of Antioxidant Capacity in Advanced Non-Small Cell Lung Cancer

    Acta Oncologica Turcica, 2020

    DOI 10.5505/aot.2020.35582 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  43. The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer

    Tuberk Toraks, 2020

    DOI 10.5578/tt.69182 PMID 32755111 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  44. A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint

    Current Medical Research and Opinion, 2020

    DOI 10.1080/03007995.2020.1716705 PMID 31942809 5 citations (OpenAlex) Source : OpenAlex

  45. The incidence and prognostıc significance of sarcopenia in advanced gastric cancer patients

    AYBU AVESIS, 2020

    Source : OpenAlex

  46. The investigation of the related factors that affected targeted therapy outcome in metastatic colon cancer

    AYBU AVESIS, 2020

    Source : OpenAlex

  47. THE INCIDENCE AND PROGNOSTICSIGNIFICANCE OF SARCOPENIA IN ADVANCEDGASTRIC CANCER PATIENTS

    AYBU AVESIS, 2020

    Source : OpenAlex

  48. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

    Journal of Oncology Pharmacy Practice, 2019

    DOI 10.1177/1078155219883004 PMID 31653193 17 citations (Europe PMC) Source : OpenAlex

  49. Evaluation of dynamic serum thiol-disulphide homeostasis in colorectal cancer

    Journal of Oncological Sciences, 2019

    DOI 10.1016/j.jons.2019.08.001 4 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  50. An update on immunotherapy options for urothelial cancer

    Expert Opinion on Biological Therapy, 2019

    DOI 10.1080/14712598.2019.1667975 PMID 31518156 13 citations (OpenAlex) Source : OpenAlex